Skip to main content
. Author manuscript; available in PMC: 2013 May 3.
Published in final edited form as: Clin Gastroenterol Hepatol. 2012 May 18;10(10):1143–1151. doi: 10.1016/j.cgh.2012.05.003

Figure 2. Treatment Strategies.

Figure 2

* In quiescent disease, the 5-ASA dose was mesalamine 2.4 g po qD (“maintenance 5-ASA”). In active disease, the oral 5-ASA dose was doubled, and mesalamine enemas (4 g per rectum each day) were added (“intensive 5-ASA”). ** Flare on infliximab therapy led to colectomy.